1. Home
  2. MCRB vs CMT Comparison

MCRB vs CMT Comparison

Compare MCRB & CMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MCRB
  • CMT
  • Stock Information
  • Founded
  • MCRB 2010
  • CMT 1996
  • Country
  • MCRB United States
  • CMT United States
  • Employees
  • MCRB N/A
  • CMT N/A
  • Industry
  • MCRB Biotechnology: Pharmaceutical Preparations
  • CMT Electronic Components
  • Sector
  • MCRB Health Care
  • CMT Consumer Discretionary
  • Exchange
  • MCRB Nasdaq
  • CMT Nasdaq
  • Market Cap
  • MCRB 165.3M
  • CMT 166.5M
  • IPO Year
  • MCRB 2015
  • CMT N/A
  • Fundamental
  • Price
  • MCRB $17.23
  • CMT $21.38
  • Analyst Decision
  • MCRB Hold
  • CMT
  • Analyst Count
  • MCRB 4
  • CMT 0
  • Target Price
  • MCRB $73.67
  • CMT N/A
  • AVG Volume (30 Days)
  • MCRB 245.5K
  • CMT 35.4K
  • Earning Date
  • MCRB 11-12-2025
  • CMT 11-04-2025
  • Dividend Yield
  • MCRB N/A
  • CMT N/A
  • EPS Growth
  • MCRB N/A
  • CMT N/A
  • EPS
  • MCRB 10.22
  • CMT 1.08
  • Revenue
  • MCRB N/A
  • CMT $276,176,000.00
  • Revenue This Year
  • MCRB N/A
  • CMT N/A
  • Revenue Next Year
  • MCRB N/A
  • CMT $6.42
  • P/E Ratio
  • MCRB $1.68
  • CMT $20.21
  • Revenue Growth
  • MCRB N/A
  • CMT N/A
  • 52 Week Low
  • MCRB $6.53
  • CMT $12.25
  • 52 Week High
  • MCRB $24.67
  • CMT $22.00
  • Technical
  • Relative Strength Index (RSI)
  • MCRB 52.55
  • CMT 69.15
  • Support Level
  • MCRB $17.00
  • CMT $21.04
  • Resistance Level
  • MCRB $24.67
  • CMT $22.00
  • Average True Range (ATR)
  • MCRB 1.79
  • CMT 0.68
  • MACD
  • MCRB -1.40
  • CMT 0.14
  • Stochastic Oscillator
  • MCRB 69.86
  • CMT 81.41

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

About CMT Core Molding Technologies Inc

Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam, and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.

Share on Social Networks: